Top Page
Animalcare
(LSE:ANCR)
Animalcare (ANCR) vs. iShares MSCI United Kingdom ETF (EWC)
Animalcare Business Overview & Revenue Model
Animalcare Financial Statement Overview
| Breakdown | ||||
| Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|
| Income Statement | Total Revenue | |||
| 74.23M | 74.35M | 71.62M | 74.02M | 70.49M | Gross Profit |
| 34.06M | 43.35M | 40.66M | 39.42M | 36.56M | EBIT |
| 4.50M | 4.41M | 3.24M | 1.99M | 2.59M | EBITDA |
| 13.43M | 12.23M | 11.04M | 10.15M | 10.30M | Net Income Common Stockholders |
| 32.22M | 1.20M | 1.97M | -77.00K | 234.00K |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
| 11.71M | 4.64M | 6.04M | 5.63M | 5.26M | Total Assets |
| 158.81M | 106.79M | 118.24M | 110.00M | 124.44M | Total Debt |
| 23.16M | 5.88M | 11.44M | 10.96M | 18.88M | Net Debt |
| 11.45M | 1.23M | 5.40M | 5.33M | 13.62M | Total Liabilities |
| 45.50M | 28.90M | 39.26M | 31.20M | 42.84M | Stockholders Equity |
| 113.31M | 77.89M | 78.99M | 78.80M | 81.59M |
| Cash Flow | Free Cash Flow | |||
| 11.72M | 7.73M | 6.48M | 10.81M | 8.68M | Operating Cash Flow |
| 11.93M | 10.28M | 9.43M | 14.02M | 11.12M | Investing Cash Flow |
| -34.85M | -2.86M | -3.12M | -2.96M | -2.91M | Financing Cash Flow |
| 32.53M | -8.95M | -5.70M | -10.96M | -8.86M |
Animalcare Technical Analysis
Animalcare Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
81 Outperform | £195.93M | 5.27 | 33.70% | 1.41% | -0.17% | 2591.96% | |
71 Outperform | £4.73B | 16.77 | 15.79% | 2.69% | 5.83% | 83.35% | |
62 Neutral | £42.69M | 63.40 | 0.80% | ― | -4.37% | ― | |
59 Neutral | $355.92M | ― | -5.04% | ― | -1.02% | 67.70% | |
59 Neutral | £178.70M | ― | ― | -16.14% | -68.06% | ||
54 Neutral | $5.41B | 3.27 | -45.10% | 3.29% | 16.81% | 0.02% | |
51 Neutral | £314.59M | ― | -369.20% | ― | 4.50% | 74.32% |
Animalcare Corporate Events
Animalcare Group plc has acquired a 25% equity stake in InVetro Pty Ltd, an Australian-based Companion Animal health business, for A$3 million. This strategic investment is part of Animalcare’s geographic expansion strategy, aiming to establish a presence in the fast-growing Companion Animal health market in Australia and potentially other Asia-Pacific territories. The investment will enable InVetro to scale its commercial operations, expand its product portfolio, and develop new products. Animalcare’s long-term goal is to build a Companion Animal business in the region with revenues of A$20-25 million. The partnership provides Animalcare with immediate market access, leveraging InVetro’s local expertise and regulatory capabilities, and sets the stage for future collaboration and increased ownership.
The most recent analyst rating on (GB:ANCR) stock is a Buy with a £290.00 price target. To see the full list of analyst forecasts on Animalcare stock, see the GB:ANCR Stock Forecast page.
Animalcare Group plc announced that all resolutions proposed at its 2025 Annual General Meeting were approved. The resolutions included the receipt of audited accounts, declaration of a final dividend, re-election of directors, and authorization for share allotment and purchase. This outcome reflects strong shareholder support and positions the company to continue its strategic initiatives and maintain its market presence.
The most recent analyst rating on (GB:ANCR) stock is a Buy with a £290.00 price target. To see the full list of analyst forecasts on Animalcare stock, see the GB:ANCR Stock Forecast page.
Animalcare Group plc has announced the exercise of options under its Long Term Incentive Plan, resulting in the issuance of 4,157 new ordinary shares. These shares will commence trading on AIM on 4 June 2025 and will be fully paid, ranking equally with existing shares. Following this issuance, the total number of shares with voting rights will be 68,989,072, providing a new denominator for shareholders to calculate their interests under the FCA’s rules.
The most recent analyst rating on (GB:ANCR) stock is a Buy with a £290.00 price target. To see the full list of analyst forecasts on Animalcare stock, see the GB:ANCR Stock Forecast page.
Animalcare Group plc, an international animal health business, announced the exercise of options under its Long Term Incentive Plan, resulting in the issuance of 4,157 new ordinary shares. These shares will be admitted to trading on AIM on June 4, 2025, and will carry the same rights as existing shares, including voting rights. This issuance increases the total number of shares with voting rights to 68,989,072, impacting shareholder calculations under the FCA’s Disclosure and Transparency Rules.
The most recent analyst rating on (GB:ANCR) stock is a Buy with a £290.00 price target. To see the full list of analyst forecasts on Animalcare stock, see the GB:ANCR Stock Forecast page.
Animalcare Group PLC has announced a change in its major holdings, with Harwood Capital LLP adjusting its voting rights in the company. The notification indicates that Harwood Capital LLP’s voting rights have decreased from 10.232840% to 9.929000%, reflecting a slight reduction in their stake. This adjustment in holdings could influence the company’s governance and decision-making processes, potentially impacting its strategic direction and stakeholder interests.
The most recent analyst rating on (GB:ANCR) stock is a Buy with a £290.00 price target. To see the full list of analyst forecasts on Animalcare stock, see the GB:ANCR Stock Forecast page.
Animalcare Group plc has published its 2024 Annual Report and Financial Statements, along with the Notice of its 2025 Annual General Meeting. The AGM is scheduled for 10 June 2024 in London. This release highlights the company’s commitment to transparency and shareholder engagement, potentially impacting its market positioning and stakeholder relations positively.
The most recent analyst rating on (GB:ANCR) stock is a Buy with a £290.00 price target. To see the full list of analyst forecasts on Animalcare stock, see the GB:ANCR Stock Forecast page.
Animalcare Group PLC announced a correction to the dividend payment timetable for the year ended 31 December 2024. The Board proposes a final dividend of 3.0 pence per share, consistent with the previous year, pending shareholder approval at the Annual General Meeting on 10 June 2025. The dividend will be paid on 18 July 2025, with shares becoming ex-dividend on 19 June 2025. This announcement maintains the company’s commitment to returning value to shareholders, reflecting stability in its financial strategy.
Animalcare Group plc reported strong financial performance for the year ended December 2024, with revenues from continuing operations increasing by 4.9% to £74.2m. The company completed a transformational acquisition of Randlab, enhancing its position in the equine sector and expanding its reach into the Asia Pacific markets. The acquisition, along with the sale of non-core assets, strengthened the balance sheet and supported both organic and inorganic growth strategies. The Group’s strategic focus on R&D and product development, particularly in the novel VHH antibody program, positions it well for future growth. The company’s robust financial health and strategic acquisitions underscore its commitment to long-term growth and market expansion.
Animalcare Group PLC has announced a change in its voting rights structure due to an acquisition of shares by SEB Funds AB, a Swedish entity. This acquisition has resulted in SEB Funds AB holding 5.018261% of the voting rights in Animalcare, potentially impacting the company’s decision-making processes and shareholder dynamics.
Animalcare Group plc has announced that it will release its financial results for the year ended 31 December 2024 on 29 April 2025. The company will host virtual presentations for analysts and investors to discuss the results, with CEO Jenny Winter and CFO Chris Brewster leading the sessions. This announcement highlights Animalcare’s commitment to transparency and engagement with stakeholders, potentially impacting its market positioning and investor relations.